Literature DB >> 22311342

Outcome of Henoch-Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset.

Outi Jauhola1, Jaana Ronkainen, Olli Koskimies, Marja Ala-Houhala, Pekka Arikoski, Tuula Hölttä, Timo Jahnukainen, Jukka Rajantie, Timo Örmälä, Matti Nuutinen.   

Abstract

BACKGROUND: Corticosteroids have been shown not to prevent the development of Henoch-Schönlein nephritis. However, long-term follow-up data are scarce.
METHODS: The long-term outcome of patients in a randomized placebo-controlled prednisone study was evaluated 8 years later with a health questionnaire completed by 160/171 (94%) patients and by urine and blood pressure screening (138/171, 81%).
RESULTS: Twelve patients had hematuria and/or proteinuria and seven had hypertension. The patients with nephritis at onset of Henoch-Schönlein purpura (HSP) had an increased risk of hypertension and/or urine abnormalities (odds ratio 3.6, p = 0.022, 95% confidence interval 1.3-10.0). There were no differences between the prednisone and placebo groups. Recurrences of purpura were reported by 15 patients, with some recurrences continuing for 10 years. All five reported pregnancies were complicated by proteinuria. Four patients presented with hematuria and/or proteinuria at the control visit, and four had hypertension. Of these, two had a decreased estimated glomerular filtration rate.
CONCLUSIONS: HSP has a good long-term prognosis in unselected patients, although skin relapses with/without late-onset nephritis may occur, even a decade after the initial disease. Urine and blood pressure abnormalities 8 years after HSP are associated with nephritis at its onset. Early prednisone treatment does not affect the outcome and should not be routinely used.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22311342     DOI: 10.1007/s00467-012-2106-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  34 in total

1.  Recurrent Henoch-Schönlein purpura in children.

Authors:  Dario Prais; Jacob Amir; Moshe Nussinovitch
Journal:  J Clin Rheumatol       Date:  2007-02       Impact factor: 3.517

2.  Predictors of outcome in Henoch-Schönlein nephritis in children and adults.

Authors:  Rosanna Coppo; Simeone Andrulli; Alessandro Amore; Bruno Gianoglio; Giovanni Conti; Licia Peruzzi; Francesco Locatelli; Leonardo Cagnoli
Journal:  Am J Kidney Dis       Date:  2006-06       Impact factor: 8.860

Review 3.  Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature.

Authors:  F T Saulsbury
Journal:  Medicine (Baltimore)       Date:  1999-11       Impact factor: 1.889

4.  Clinical outcome in children with Henoch-Schönlein nephritis.

Authors:  Sevgi Mir; Onder Yavascan; Fatma Mutlubas; Betul Yeniay; Ferah Sonmez
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

5.  Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents.

Authors: 
Journal:  Pediatrics       Date:  1996-10       Impact factor: 7.124

6.  Henoch Schönlein nephritis: clinical findings related to renal function and morphology.

Authors:  Stella F Edström Halling; Magnus P Söderberg; Ulla B Berg
Journal:  Pediatr Nephrol       Date:  2004-10-22       Impact factor: 3.714

7.  Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children.

Authors:  Outi Jauhola; Jaana Ronkainen; Olli Koskimies; Marja Ala-Houhala; Pekka Arikoski; Tuula Hölttä; Timo Jahnukainen; Jukka Rajantie; Timo Ormälä; Juha Turtinen; Matti Nuutinen
Journal:  Arch Dis Child       Date:  2010-09-18       Impact factor: 3.791

8.  EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria.

Authors:  Seza Ozen; Angela Pistorio; Silvia M Iusan; Aysin Bakkaloglu; Troels Herlin; Riva Brik; Antonella Buoncompagni; Calin Lazar; Ilmay Bilge; Yosef Uziel; Donato Rigante; Luca Cantarini; Maria Odete Hilario; Clovis A Silva; Mauricio Alegria; Ximena Norambuena; Alexandre Belot; Yackov Berkun; Amparo Ibanez Estrella; Alma Nunzia Olivieri; Maria Giannina Alpigiani; Ingrida Rumba; Flavio Sztajnbok; Lana Tambic-Bukovac; Luciana Breda; Sulaiman Al-Mayouf; Dimitrina Mihaylova; Vyacheslav Chasnyk; Claudia Sengler; Maria Klein-Gitelman; Djamal Djeddi; Laura Nuno; Chris Pruunsild; Jurgen Brunner; Anuela Kondi; Karaman Pagava; Silvia Pederzoli; Alberto Martini; Nicolino Ruperto
Journal:  Ann Rheum Dis       Date:  2010-05       Impact factor: 19.103

9.  Variation in inpatient therapy and diagnostic evaluation of children with Henoch Schönlein purpura.

Authors:  Pamela F Weiss; Andrew J Klink; Kari Hexem; Jon M Burnham; Mary B Leonard; Ron Keren; Russell Localio; Chris Feudtner
Journal:  J Pediatr       Date:  2009-07-29       Impact factor: 4.406

10.  A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383].

Authors:  Adam M Huber; Jim King; Peter McLaine; Terry Klassen; Mary Pothos
Journal:  BMC Med       Date:  2004-04-02       Impact factor: 8.775

View more
  18 in total

1.  Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schönlein purpura nephritis.

Authors:  Jean-Claude Davin; Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2013-07-09       Impact factor: 3.714

2.  Establishing hospital admission criteria of pediatric Henoch-Schonlein purpura.

Authors:  Kamal Masarweh; Yoseph Horovitz; Avi Avital; Ronen Spiegel
Journal:  Rheumatol Int       Date:  2014-02-23       Impact factor: 2.631

3.  Urinary MCP-1/creatinine in Henoch-Schönlein purpura and its relationship with nephritis.

Authors:  Yolanda Fuentes; Ana María Hernández; Pilar García-Roca; Saúl Valverde; Luis Fernando Velásquez-Jones; Germán Sosa; Uriel Oswaldo Duarte-Durán; Lourdes Ortíz; Rocío Maldonado; Enrique Faugier; Guillermo Ramón-García; Mara Medeiros
Journal:  Pediatr Nephrol       Date:  2014-01-12       Impact factor: 3.714

4.  Henoch-Schönlein purpura in children: limited benefit of corticosteroids.

Authors:  Joel Bluman; Ran D Goldman
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

5.  Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study.

Authors:  Mikael Koskela; Timo Jahnukainen; Kira Endén; Pekka Arikoski; Janne Kataja; Matti Nuutinen; Elisa Ylinen
Journal:  Pediatr Nephrol       Date:  2019-04-06       Impact factor: 3.714

Review 6.  Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature.

Authors:  Roberta Fenoglio; Carla Naretto; Bruno Basolo; Giacomo Quattrocchio; Michela Ferro; Paola Mesiano; Giulietta Beltrame; Dario Roccatello
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

7.  The relationship of neutrophil-to-lymphocyte ratio with gastrointestinal bleeding in Henoch-Schonlein purpura.

Authors:  Balahan Makay; Özge Altuğ Gücenmez; Murat Duman; Erbil Ünsal
Journal:  Rheumatol Int       Date:  2014-03-20       Impact factor: 2.631

Review 8.  IgA Vasculitis and IgA Nephropathy: Same Disease?

Authors:  Evangeline Pillebout
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

Review 9.  Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP).

Authors:  Deirdre Hahn; Elisabeth M Hodson; Narelle S Willis; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-08-07

10.  The Optimal Cut-Off Value of Neutrophil-to-Lymphocyte Ratio for Predicting Prognosis in Adult Patients with Henoch-Schönlein Purpura.

Authors:  Chan Hyuk Park; Dong Soo Han; Jae Yoon Jeong; Chang Soo Eun; Kyo-Sang Yoo; Yong Cheol Jeon; Joo Hyun Sohn
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.